RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30 avr. 2024 10h00 HE
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
25 avr. 2024 10h00 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
Global Interventional Pulmonology Market Analysis Report 2024-2028: Robotic Bronchoscopy is Emerging as a Game Changer in the $5+ Billion Industry
16 avr. 2024 07h32 HE
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ...
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18 mars 2024 11h30 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
Chronic Disease Management Market revenue to reach USD 27 Billion by 2035, says Research Nester
13 mars 2024 07h30 HE
|
Research Nester
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The global chronic disease management market size is projected to grow at a CAGR of over ~13% from 2023 to 2035. The market is expected to garner a...
Monaghan Medical Corporation Attains ISO 14001 Certification for Environmental Management Excellence
27 févr. 2024 07h00 HE
|
Monaghan Medical Corporation
Monaghan Medical Corporation is proud to have achieved ISO 14001 certification
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23 févr. 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...
RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
21 févr. 2024 09h52 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce the formation of its Therapeutic Expert Council (TEC).
Pulmonary Drug Delivery Devices Market revenue to hit USD 105 Billion by 2035, says Research Nester
31 janv. 2024 05h30 HE
|
Research Nester
New York, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The global pulmonary drug delivery devices market size is predicted to expand at ~7% CAGR between 2023 and 2035. The market is projected to garner a...
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
07 déc. 2023 15h34 HE
|
ResMed Inc.
New study shows Chronic Obstructive Pulmonary Disease (COPD) increasing globally through 2050, with 47% growth among women.